ALNY
ALNYLAM PHARMACEUTICALS, INC.
- PER (TTM)
- 74.13
- PER (Forward)
- 21.27
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 36.61
- 시가총액
- 39.39B
- 배당수익률
- -
- 베타
- 0.30
- 1개월 수익률
- -8.16%
- 3개월 수익률
- -10.09%
- 6개월 수익률
- -32.10%
- 1년 수익률
- 6.69%
- 2년 수익률
- -
- 5일 평균거래량
- 1099500
- 60일 평균거래량
- 1170070
- 1년 평균거래량
- 1198767
- 5d/60d 거래량 비율
- 0.94×
- 60d/1y 거래량 비율
- 0.98×
- 변동성(60일, 연환산)
- 36.59%
- BB 스퀴즈 스코어
- 1.01
- SMA50 비율
- 0.93
- SMA200 비율
- 0.75
- RSI (14)
- 39
- 20일 수렴도
- 0.04
- 52주 최고
- 491.22
- 52주 최저
- 251.15
- 고점 대비
- -39.94%
- 저점 대비
- 17.48%
펀더멘털 갱신: 2026-05-10T07:37:27+00:00 · 시세 갱신: 2026-05-10T06:08:11+00:00
회사 정보
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.